Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2019-09-23 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces the results of a clinical study (ENGAGE) regarding the drug Dysport®. It details study methodology, primary endpoints, and quotes key personnel. This format—a formal announcement of new scientific or clinical data, often timed around a conference presentation (MDS Congress mentioned)—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing like a proxy statement, and it focuses on presenting new data/results, it aligns best with an Earnings Release (ER) which often includes significant operational or clinical milestones, or potentially an Investor Presentation (IP) if it were structured as slides, but the press release format strongly suggests an ER or a related announcement. Given the content is a detailed announcement of clinical trial results, which often accompanies or precedes an earnings report, and it is not a brief notification of a report's publication (RPA), the most fitting category for a major, non-financial operational announcement of this nature is the Earnings Release (ER), as these releases frequently contain key operational/clinical achievements alongside financial highlights, or it serves as the primary vehicle for communicating such news to the market. However, looking closely at the definitions, this is purely a clinical/scientific announcement about a drug study, not a periodic financial results announcement (ER). It is a press release detailing study outcomes. If the company were announcing its quarterly results, this might be attached, but in isolation, it's a specific scientific update. Since there is no specific category for 'Clinical Trial Results Announcement', we must choose the closest fit. It is not a presentation (IP), nor a general regulatory filing (RNS). It is a formal communication of new information to the market. Given the options, and recognizing that press releases announcing significant operational/scientific milestones often fall under the umbrella of 'Earnings Release' communication strategies, or sometimes 'Regulatory Filings' (RNS) if it were mandatory disclosure, I will re-evaluate. Since it is a detailed announcement of study results, it is more substantial than a simple RNS, and not a financial report. It is closest in function to an Investor Presentation (IP) in terms of content depth, but the format is a press release. In many databases, detailed press releases announcing clinical data are classified as ER if they are market-moving, or RNS if they are mandatory disclosures. Since it is a detailed announcement of study results, and not a brief notification of a report's publication (RPA), and it is not a full financial report, I will classify it as an Investor Presentation (IP) due to the depth of data presented, even though the format is a press release, as it serves the function of presenting detailed data to investors. Revisiting the definitions: IP is 'Detailed presentation for investors focusing on financials, strategy, and market position.' This document focuses heavily on strategy/product data. ER is 'Initial announcement of quarterly/periodical financial results (key highlights only).' This is not primarily financial highlights. Given the depth and focus on study results intended for investors, IP is a strong candidate. If it were purely mandatory disclosure without the marketing/investor spin, RNS would be better. I will stick with IP as the content is a detailed presentation of clinical data aimed at investors/market perception.
2019-09-23 French
Inside Information / Other news releases
Earnings Release Classification · 98% confidence The document is titled "PRESS RELEASE" and announces that Ipsen will present new data at the 13th Annual Conference of the International Liver Cancer Association (ILCA 2019). It details the results of a matching-adjusted indirect comparison (MAIC) study regarding cabozantinib versus regorafenib for advanced hepatocellular carcinoma (aHCC). This content is a scientific/clinical update intended for investors and healthcare professionals, focusing on trial results and comparative effectiveness. It is not a formal regulatory filing like a 10-K, a quarterly report (IR), or a simple earnings release (ER). It is a detailed presentation of clinical findings, which aligns best with an Investor Presentation (IP) or a detailed announcement that often accompanies such presentations. Given the focus on presenting detailed clinical data and comparisons (MAIC analysis, Phase III trial details like CELESTIAL), 'Investor Presentation' (IP) is the most appropriate classification, as these press releases often serve as the textual basis or summary for an investor presentation deck. It is not an RPA because it is the substantive content itself, not just an announcement that a report is available. It is too detailed for a simple ER or FS. It is not a CT as it is a press release, not a transcript. Therefore, IP is the best fit. FY 2019
2019-09-20 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 99% confidence The document is a press release from Ipsen dated September 20, 2019, announcing that new data comparing cabozantinib and regorafenib for advanced hepatocellular carcinoma (HCC) will be presented at the 13th International Liver Cancer Association (ILCA 2019) conference. The text details the results of a Matching-Adjusted Indirect Comparison (MAIC) study (CELESTIAL vs. RESORCE trials) and provides extensive background on the drug, the disease, and the clinical trials (CELESTIAL). This content structure—announcing data presentation, summarizing clinical findings, and providing product/disease background—is characteristic of an Investor Presentation (IP) or a detailed press release that functions as one, rather than a brief Earnings Release (ER) or a formal regulatory filing like a 10-K or IR. Since it is a detailed presentation of clinical data and strategy aimed at investors/analysts, Investor Presentation (IP) is the most appropriate classification. It is not a short announcement of a report publication (RPA) because it contains substantial, detailed content. FY 2019
2019-09-20 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Monthly information regarding the total number of voting rights and total number of shares of the Company" and references Article 223-16 of the AMF General Regulations. It provides a table detailing the total number of shares and voting rights as of a specific date (August 31, 2019). This content specifically relates to the disclosure of voting rights and share capital structure, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA), as it is a periodic disclosure concerning voting rights, even if it's not the final result of a specific vote. It is a specific regulatory disclosure related to voting rights.
2019-09-16 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of a specific date (August 31, 2019). This content directly relates to changes in the capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA), as it reports the current state of the capital base and voting power. Although it is a monthly report, the core subject matter is the capital structure, not just a general regulatory announcement (RNS) or a dividend notice (DIV).
2019-09-16 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated September 8, 2019, announcing initial clinical data for an investigational drug (liposomal irinotecan/ONIVYDE®) presented at a major medical conference (IASLC 2019 World Conference on Lung Cancer). It details safety and efficacy results (ORR, DCR12wks) from Part 1 of the RESILIENT study, includes detailed safety warnings (BOXED WARNINGS), and provides background on the drug and the companies (Ipsen and Servier). This content structure—announcing clinical trial results and associated safety information outside of a formal regulatory filing like a 10-K or a comprehensive quarterly report (IR)—is characteristic of an Earnings Release (ER) or a general press announcement regarding clinical progress. Since it focuses on the release of new data/results, 'ER' (Earnings Release) is the most appropriate fit among the provided options, as it often encompasses significant operational/clinical updates released to the market, even if not strictly quarterly financial earnings. It is not a transcript (CT), a formal annual report (10-K), or a presentation deck (IP). Given the focus on presenting new data, ER is the best fit.
2019-09-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.